Division of Dermatology and Dermatopathology, Nippon Medical School Musashi Kosugi-Hospital, Kawasaki, Japan.
Department of Dermatology, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan.
J Dermatol. 2021 Jul;48(7):e288-e311. doi: 10.1111/1346-8138.15889. Epub 2021 May 7.
In consideration of the development of treatment options for squamous cell carcinoma (SCC), the Japanese Skin Cancer Society issued the first guidelines of SCC in 2007 and revised them in 2015. Here, we report the English version of the 2020 edition of the Japanese SCC guidelines. The first half of this article is an overview of SCC including actinic keratosis and Bowen's disease, and the second half discusses three clinical questions: (i) treatment of actinic keratosis; (ii) determination of the resection margin of the primary lesion; and (iii) treatment of radically incurable cases, as contemporary problems encountered in treating SCC. In these evaluations, all processes were implemented according to the Grading of Recommendations, Assessment, Development, Evaluation system. Also, items of recommendation concerning each clinical question were determined by a multidisciplinary expert panel consisting of dermatologists, plastic/reconstructive surgeons, radiologists, and oncologists through a comprehensive literature search and systematic reviews.
考虑到鳞状细胞癌(SCC)治疗方案的发展,日本皮肤科学会于 2007 年发布了 SCC 的第一版指南,并于 2015 年进行了修订。在这里,我们报告了 2020 年版日本 SCC 指南的英文版本。本文的前半部分是 SCC 的概述,包括光化性角化病和 Bowen 病,后半部分讨论了三个临床问题:(i)光化性角化病的治疗;(ii)原发性病变切除边缘的确定;以及(iii)根治性不可治愈病例的治疗,这些都是治疗 SCC 时遇到的当代问题。在这些评估中,所有流程均根据推荐分级、评估、发展、评估系统进行实施。此外,通过全面的文献检索和系统评价,由皮肤科医生、整形/重建外科医生、放射科医生和肿瘤学家组成的多学科专家小组确定了每个临床问题的推荐项目。